Английская Википедия:Indacaterol
Шаблон:Short description Шаблон:Drugbox Indacaterol is an ultra-long-acting beta-adrenoceptor agonist[1] developed by Novartis. It needs to be taken only once a day,[2] unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.
Medical uses
A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.[3]
History
It was approved by the European Medicines Agency (EMA) under the brand name Onbrez Breezhaler on November 30, 2009,[4] and by the United States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011.[5][6] In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals.[7]
References
Шаблон:Adrenergic agonists Шаблон:Asthma and copd rx
